In a breakthrough in the understanding of how cancer does its deadly work, researchers at the University of Virginia have shown that many cancers, including nearly all pancreatic cancers, enslave and deform mitochondria, the powerhouses of cells, to create an environment more conducive to tumour growth. In such cases, the researchers have shown, the mitochondria are being forced to divide unnaturally, to lose their normal shape and collapse around the cell’s nucleus. The end result is an environment more hospitable to cancer. By blocking this process, doctors one day may be able to block the growth of such tumours. The opensource study is published in the journal Molecular Cell.
The data findings suggest that in combination with other inhibitors, the medical community may one day target this process of mitochondrial division, mitochondrial fission.
The current study looked at tumours caused by mutations in the gene Ras, which is mutated in up to 30 percent of all cancers. Ras activates a cellular signaling pathway, the MAP kinase pathway, that was discovered by the team in previous studies. That cellular communication is prompting mitochondria to act very strangely, to divide with a frequency they normally wouldn’t.
While mitochondria are popularly thought to resemble beans floating in the cellular cytoplasm, recent research has shown they’re actually long, stringy interconnected networks that constantly fuse and divide. The team state that Ras appears to send that division process into overdrive, both in mouse models and in cell lines created from human pancreatic cancer samples. The current study saw a similar finding in both, when the team knocked down the cells’ ability to divide their mitochondria, they blocked tumour growth.
The team state that the data findings point to a promising new target for developing cancer drugs, adding that over the years the medical community has identified vulnerabilities in some of the pathways activated by Ras, targets that can inhibit tumour growth for a short time. However, the problem is that the tumours always find a way to come back. The team surmise that additional targets are needed and what this new study may provide is an additional target in Ras and MAP kinase-driven cancers.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.